Have your own idea? Try our Stock Screener
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by pullbacks in Regeneron Pharmaceuticals and Alnylam Pharmaceuticals of 2.7% and 9.4%, respectively. Meanwhile, Vaxcyte actually outperformed within the industry, gaining 40% in the last week. In the past year, the industry has gained 13%. Looking forward, earnings are forecast to grow by 30% annually.
Has the U.S. Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Thu, 05 Sep 2024 | US$889.8b | US$113.1b | -US$35,706,110,149.34 | 23.3x | -24.9x | 7.9x |
Sat, 03 Aug 2024 | US$1.2t | US$165.9b | -US$33,221,382,510.84 | 25.9x | -36.6x | 7.3x |
Mon, 01 Jul 2024 | US$1.1t | US$164.4b | -US$27,988,781,321.07 | 28.5x | -41x | 7x |
Wed, 29 May 2024 | US$1.1t | US$164.6b | -US$26,663,229,028.47 | 27.2x | -42.2x | 6.8x |
Fri, 26 Apr 2024 | US$1.1t | US$164.2b | -US$23,382,193,080.97 | 20.1x | -46x | 6.6x |
Sun, 24 Mar 2024 | US$1.2t | US$164.3b | -US$23,936,586,653.35 | 21.4x | -48.6x | 7.1x |
Tue, 20 Feb 2024 | US$1.2t | US$169.1b | -US$20,394,485,082.32 | 15.7x | -57.5x | 6.9x |
Thu, 18 Jan 2024 | US$1.4t | US$204.8b | -US$22,506,707,794.00 | 18.8x | -63.3x | 7x |
Sat, 16 Dec 2023 | US$1.4t | US$204.7b | -US$22,119,635,723.00 | 19.2x | -61x | 6.6x |
Mon, 13 Nov 2023 | US$1.2t | US$204.5b | -US$21,996,116,562.00 | 18.5x | -54.6x | 5.9x |
Wed, 11 Oct 2023 | US$1.3t | US$207.4b | -US$13,069,383,940.00 | 17.3x | -96.7x | 6.1x |
Fri, 08 Sep 2023 | US$1.3t | US$207.5b | -US$12,639,999,993.00 | 17.3x | -100.8x | 6.1x |
Sun, 06 Aug 2023 | US$1.3t | US$210.2b | -US$10,135,599,050.00 | 15.6x | -124.3x | 6x |
Tue, 04 Jul 2023 | US$1.1t | US$186.3b | -US$16,037,705,056.00 | 13.4x | -69.9x | 6x |
Thu, 01 Jun 2023 | US$1.1t | US$185.9b | -US$16,012,100,305.00 | 11.4x | -69.8x | 6x |
Sat, 29 Apr 2023 | US$1.2t | US$197.1b | -US$6,647,559,484.00 | 13.7x | -174.1x | 5.9x |
Mon, 27 Mar 2023 | US$1.1t | US$199.3b | -US$3,667,886,514.00 | 13.4x | -309x | 5.7x |
Wed, 22 Feb 2023 | US$1.1t | US$202.5b | -US$166,298,506.00 | 16.4x | -6829.5x | 5.6x |
Fri, 20 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.2x | 658.6x | 5.7x |
Sun, 18 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 712.9x | 5.7x |
Tue, 15 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.9x | 1009.4x | 5.5x |
Thu, 13 Oct 2022 | US$1.0t | US$205.9b | US$5.3b | 15.2x | 195.3x | 5x |
Sat, 10 Sep 2022 | US$1.1t | US$206.4b | US$6.2b | 15.6x | 177.5x | 5.3x |
Mon, 08 Aug 2022 | US$1.1t | US$211.4b | US$8.4b | 16.7x | 131.8x | 5.3x |
Wed, 06 Jul 2022 | US$1.1t | US$211.7b | US$10.9b | 16.8x | 98.6x | 5.1x |
Fri, 03 Jun 2022 | US$994.0b | US$212.5b | US$11.1b | 15.2x | 89.4x | 4.7x |
Sun, 01 May 2022 | US$1.0t | US$200.4b | US$6.7b | 16.9x | 151.5x | 5.1x |
Tue, 29 Mar 2022 | US$1.3t | US$221.5b | US$11.8b | 19.1x | 107.6x | 5.7x |
Thu, 24 Feb 2022 | US$1.2t | US$216.0b | US$6.3b | 21.3x | 193.4x | 5.6x |
Sat, 22 Jan 2022 | US$1.2t | US$212.0b | US$2.5b | 23.1x | 493.9x | 5.8x |
Mon, 20 Dec 2021 | US$1.5t | US$211.9b | US$2.8b | 26.1x | 524x | 6.9x |
Wed, 17 Nov 2021 | US$1.5t | US$212.2b | US$3.8b | 26.9x | 383.5x | 6.9x |
Fri, 15 Oct 2021 | US$1.5t | US$196.3b | -US$2,594,144,740.00 | 23.8x | -571.3x | 7.5x |
Sun, 12 Sep 2021 | US$1.6t | US$196.4b | -US$2,267,737,004.56 | 21.1x | -697.6x | 8.1x |
-697.6x
Which industries have driven the changes within the U.S. Healthcare industry?
US Market | -1.36% | |
Healthcare | 0.19% | |
Biotech | -1.73% | |
Biotech | -1.73% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
PCVX Vaxcyte | US$109.15 | 39.2% +US$3.4b | 114.9% | PB6.1x | |
ABBV AbbVie | US$197.01 | 0.8% +US$2.8b | 35.3% | PE65.7x | |
SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
GRPH Graphite Bio | US$22.26 | 539.7% +US$1.1b | 861.6% | PB7.1x | |
BBIO BridgeBio Pharma | US$30.67 | 23.2% +US$1.1b | 4.0% | PS26.3x |